Registered title, quoted from ClinicalTrials.gov
Diagnostic Accuracy of EBV C Promoter Methylation Kit in Nasopharyngeal Carcinoma
An open trial on nasopharyngeal carcinoma, registered on ClinicalTrials.gov. Led by Sun Yat-sen University Cancer Center; 4 other hospitals on this site are listed as study sites.
Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 5
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
- Lead (inferred)Sun Yat-sen University Cancer Center中山大学肿瘤防治中心GuangzhouHospital page
- Study siteFirst Affiliated Hospital of Guangxi Medical University广西医科大学第一附属医院NanningHospital page
- Study siteFujian Cancer Hospital福建省肿瘤医院FuzhouHospital page
- Study siteWuzhou Red Cross Hospital梧州市红十字会医院WuzhouHospital page
- Study siteZhongshan City People's Hospital中山市人民医院ZhongshanHospital page
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT06445088, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
Participants who meet the following Article 1 and also meet one of Articles 2 to 6 can be enrolled:
- Understand, sign, and date the informed consent document to participate in the study
- Display one or more symptoms or signs indicative of nasopharyngeal carcinoma
- Test positive for EBV antibodies or EBV DNA
- Be diagnosed with other head and neck carcinomas
- Be diagnosed with malignancies associated with EBV infection
- Require differential diagnosis from nasopharyngeal carcinoma during endoscopic or other imaging examinations
- Fulfill any additional conditions deemed appropriate by the investigator for inclusion in this study
Exclusion Criteria:
- Have been diagnosed with nasopharyngeal carcinoma and have undergone treatment
- Experience relapse or metastasis of nasopharyngeal carcinoma following treatment
- Have unsuccessful nasopharyngeal swab collections
- Present any other conditions considered by the investigator as unsuitable for participation in this trial
Quoted from ClinicalTrials.gov, NCT06445088, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT06445088, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.